Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2017

Open Access 01-01-2017 | Original Article

PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique

Authors: Wei Guo, Bing Hao, Hao-jun Chen, Long Zhao, Zuo-ming Luo, Hua Wu, Long Sun

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2017

Login to get access

Abstract

Purpose

18F-FDG PET/CT should be performed before a diagnostic biopsy site is chosen in patients with a high clinical suspicion of aggressive, advanced tumour. The aim of this study was to evaluate the safety and efficacy of 18F-FDG PET/CT in guiding biopsy of bone metastases in patients with advanced lung cancer.

Methods

PET/CT-guided percutaneous core biopsies were performed in 51 consecutive patients with suspected lung cancer and 18F-FDG-avid bone lesions after whole-body 18F-FDG PET/CT scans. Generally, one tissue sample was obtained from each patient. The final diagnoses were established on the basis of the histology results. The histopathological and molecular testing results were systematically evaluated.

Results

A total of 53 samples were obtained for histological examination or molecular testing as a second biopsy was required in two patients in whom the pathological diagnosis was unclear following the first biopsy. The pathological diagnosis and lung cancer classification were confirmed in 48 patients. The epidermal growth factor receptor mutation status was determined in 23 biopsies, and the mutation rate was 30.4 % (7/23). The anaplastic lymphoma kinase mutation status was determined in 19 biopsies, and the mutation rate was 31.6 % (6/19). Two of the 51 biopsies were positive for non-Hodgkin’s lymphoma and one was positive for metastatic renal cell carcinoma. The first-time diagnostic success rate of biopsy was 96.1 % (49/51) and the overall diagnostic success rate and sensitivity were 100 %. All 51 patients were eventually confirmed as having stage IV disease. No serious complications were encountered and the average biopsy time was 30 min.

Conclusion

PET/CT-guided percutaneous biopsy of 18F-FDG-avid bone metastases is an effective and safe method that yields a high diagnostic success rate in the evaluation of hypermetabolic bone lesions in patients with suspected advanced lung cancer.
Literature
1.
Rebecca S, Deepa N, Ahmedin J. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRef
2.
Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, Ferrara ML, et al. Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol. 2010;2:251–60.CrossRefPubMedPubMedCentral
3.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.CrossRefPubMedPubMedCentral
4.
5.
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–6249s.CrossRefPubMed
6.
Klaeser B, Wiskirchen J, Wartenberg J, Weitzel T, Schmid RA, Mueller MD, et al. PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact. Eur J Nucl Med Mol Imaging. 2010;37:2027–36.CrossRefPubMed
7.
Cornelis F, Silk M, Schoder H, Takaki H, Durack JC, Erinjeri JP, et al. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur J Nucl Med Mol Imaging. 2014;41:2265–72.CrossRefPubMed
8.
She J, Yang P, Hong Q, Bai C. Lung cancer in china: challenges and interventions. Chest. 2013;143:1117–26.CrossRefPubMed
9.
10.
11.
Chao F, Zhang H. PET/CT in the staging of the non-small-cell lung cancer. J Biomed Biotechnol. 2012;2012:268–81.
12.
Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med. 2009;39:276–89.CrossRefPubMed
13.
Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221–8.
14.
Winn N, Spratt J, Wright E, Cox J. Patient reported experiences of CT guided lung biopsy: a prospective cohort study. Multidiscip Respir Med. 2014;9:53.CrossRefPubMedPubMedCentral
15.
Yeow KM, Su IH, Pan KT, Tsay PK, Lui KW, Cheung YC, et al. Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest. 2004;126:748–54.CrossRefPubMed
16.
Tsai IC, Tsai WL, Chen MC, Chang GC, Tzeng WS, Chan SW, et al. CT-guided core biopsy of lung lesions: a primer. AJR Am J Roentgenol. 2009;193:1228–35.CrossRefPubMed
17.
Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011;155:137–44.CrossRefPubMedPubMedCentral
18.
19.
Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S–e2150S.CrossRefPubMed
20.
Ernst A, Eberhardt R, Krasnik M, Herth FJ. Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration of hilar lymph nodes for diagnosing and staging cancer. J Thoracic Oncol. 2009;4:947–50.CrossRef
21.
Tatli S, Gerbaudo VH, Feeley CM, Shyn PB, Tuncali K, Silverman SG. PET/CT-guided percutaneous biopsy of abdominal masses: initial experience. J Vasc Interv Radiol. 2011;22:507–14.CrossRefPubMed
22.
Luo GY, Cai PQ, He JH, Li JJ, Li Y, Shan HB, et al. Application of endobronchial ultrasound-guided transbronchial needle aspiration in the management of mediastinal and hilar lymphadenopathy without intrapulmonary mass: experience from the largest cancer center of Southern China. Cell Biochem Biophys. 2013;67:1533–8.CrossRefPubMed
23.
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. Lung Cancer. 2011;72:3–8.CrossRefPubMed
24.
Mukhopadhyay S. Utility of small biopsies for diagnosis of lung nodules: doing more with less. Mod Pathol. 2012;25 Suppl 1:S43–57.
Metadata
Title
PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique
Authors
Wei Guo
Bing Hao
Hao-jun Chen
Long Zhao
Zuo-ming Luo
Hua Wu
Long Sun
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3455-9

Other articles of this Issue 1/2017

European Journal of Nuclear Medicine and Molecular Imaging 1/2017 Go to the issue

Original Article

Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT

Editorial

Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy

Original Article

The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma

Original Article

Metabolic and morphological measurements of subcutaneous and visceral fat and their relationship with disease stage and overall survival in newly diagnosed pancreatic adenocarcinoma

Erratum

Erratum to: Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM)

Review Article

Characterization of PET/CT images using texture analysis: the past, the present… any future?